EBGLYSS
Active substance: lebrikizumab
INJECTION, SOLUTION · LEBRIKIZUMAB 250 mg/2mL
United StatesActive
Marketing holder: Eli Lilly and Company
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- LEBRIKIZUMAB · 250 mg/2mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a12091-6792-78d2-8ad3-dde7c0f59b5d,01a12095-663f-7edc-9127-54b4006a0928;count=2 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 0002-7772
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 0002-7772 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 0002-7772 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 0002-7772 · Verified 2026-10-09 · open in source